| Business Summary | | Introgen
Therapeutics
Inc.
develops
gene
therapy
products
to
treat
a
variety
of
cancers.
The
Company
has
treated
over
400
patients
with
more
than
3,000
doses
of
its
lead
product
candidate,
INGN
201,
in
over
17
completed
and
ongoing
Phase
I
and
Phase
II
clinical
trials
worldwide.
Introgen's
current
and
expected
clinical
trials
evaluate
the
Company's
products
both
alone
and
in
combination
with
chemotherapy,
radiation
and/or
surgery.
Introgen
also
controls
a
broad
intellectual
property
portfolio
that
includes
more
than
200
pending
and
issued
patents
for
a
variety
of
gene
therapy
technologies.
The
Company
has
active
collaborations
with
numerous
academic
centers
and
pharmaceutical
and
biotechnology
industry
partners.
In
1998,
Introgen
Therapeutics
formed
Gendux,
a
European
subsidiary
developing
biopharmaceuticals. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Introgen
Therapeutics,
Inc.
is
a
developer
of
gene
therapy
products
for
the
treatment
of
a
variety
of
cancers.
For
the
fiscal
year
ended
6/30/01,
total
revenues
decreased
38%
to
$5.2
million.
Net
loss
totaled
$16.4
million,
up
from
$7.7
million.
Revenues
reflect
decreased
revenues
from
collaborations
due
to
a
decreased
level
of
early
stage
research
and
development.
Net
loss
reflects
increased
cost
of
sales
as
a
percentage
of
revenues
and
increased
interest
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Kapoor, Ph.D., 56 Chairman | -- | David Nance, 49 Pres,
CEO, Director | $271K | James Albrecht, Jr., 46 CFO | 176K | G. Thomas Finnegan, III VP
of Fin. and Corp. Devel. | -- | J. David Enloe, Jr, 36 VP-Operations | 162K | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|